Ignite Creation Date:
2025-12-24 @ 11:58 PM
Ignite Modification Date:
2025-12-25 @ 9:55 PM
Study NCT ID:
NCT04488458
Status:
UNKNOWN
Last Update Posted:
2021-08-24
First Post:
2020-07-10
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Susceptibility Testing of Biofilm to Guide Treatment of Periprosthetic Joint Infections
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'interventionBrowseModule': {'meshes': [{'id': 'D008826', 'term': 'Microbial Sensitivity Tests'}], 'ancestors': [{'id': 'D008828', 'term': 'Microbiological Techniques'}, {'id': 'D019411', 'term': 'Clinical Laboratory Techniques'}, {'id': 'D019937', 'term': 'Diagnostic Techniques and Procedures'}, {'id': 'D003933', 'term': 'Diagnosis'}, {'id': 'D008919', 'term': 'Investigative Techniques'}, {'id': 'D004353', 'term': 'Drug Evaluation, Preclinical'}, {'id': 'D005069', 'term': 'Evaluation Studies as Topic'}]}}, 'protocolSection': {'designModule': {'phases': ['NA'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'NONE'}, 'primaryPurpose': 'DIAGNOSTIC', 'interventionModel': 'PARALLEL'}, 'enrollmentInfo': {'type': 'ESTIMATED', 'count': 40}}, 'statusModule': {'overallStatus': 'UNKNOWN', 'lastKnownStatus': 'RECRUITING', 'startDateStruct': {'date': '2021-08-15', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2021-07', 'completionDateStruct': {'date': '2023-12-31', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2021-08-18', 'studyFirstSubmitDate': '2020-07-10', 'studyFirstSubmitQcDate': '2020-07-22', 'lastUpdatePostDateStruct': {'date': '2021-08-24', 'type': 'ACTUAL'}, 'studyFirstPostDateStruct': {'date': '2020-07-28', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2022-12-31', 'type': 'ESTIMATED'}}, 'outcomesModule': {'otherOutcomes': [{'measure': 'Correlation between the virulence properties of the causative bacteria and patient outcome (infection resolution versus recurrent infection)', 'timeFrame': '36 months', 'description': 'The staphylococcal strains isolated from the patients with PJI will be characterised by phenotypic tests and whole genome sequencing to determine their virulence properties and carriage of genes involved in biofilm formation, antimicrobial resistance and production of toxins. Then the particular virulence of the strains will be correlated to the patients outcome, to be able to assess if more virulence carriage correlates to worse outcome (recurrent infection)'}], 'primaryOutcomes': [{'measure': 'Number of changes in antimicrobial regimen other than standard of care', 'timeFrame': '6 weeks', 'description': 'Proportions of antimicrobial regimens other than standard of care through application of proposed MBEC-algorithm.'}], 'secondaryOutcomes': [{'measure': 'Repeat procedure, relapse or reinfection', 'timeFrame': '12 months', 'description': 'Number of repeat procedures, relapses or reinfections, according to MSIS-criteria of PJI'}, {'measure': 'Oxford Hip Score', 'timeFrame': '12 months', 'description': 'Hip specific patient-reported outcome measure'}, {'measure': 'EQ-5D', 'timeFrame': '12 months', 'description': 'Generic health status patient-reported outcome measure'}, {'measure': 'Time to revision', 'timeFrame': '12 months', 'description': 'A shorter time could potentially indicate that the right decision is taken at an earlier stage'}, {'measure': 'Inpatient care', 'timeFrame': 'Up to 12 months', 'description': 'Resource consumption measure (days).'}, {'measure': 'Outpatient visits', 'timeFrame': 'Up to 12 months', 'description': 'Resource consumption measure, number of visits, type of visits.'}, {'measure': 'Discharge destination', 'timeFrame': 'Up to 12 months', 'description': 'Resource consumption measure. The type of facility a patient is discharged to (rehab facility, nursing home, home, home care).'}, {'measure': 'Heath care costs', 'timeFrame': 'Up to 12 months', 'description': 'Compound measure using data from outcome 6-8 (currency EUR).'}, {'measure': 'Development of additional antimicrobial resistance of the relapse causative strain', 'timeFrame': '12 months', 'description': 'At relapse surgery, the causative strain will be isolated by new biopsy cultures. Then the susceptibility of the causative strain will be tested again to evaluate any possible emergence of resistance against the antimicrobials previously used in the study. This will confirm if the given antimicrobial treatment has lead to antimicrobial resistance in a potential relapse strain isolated at a later occasion.'}]}, 'oversightModule': {'oversightHasDmc': False, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'keywords': ['staphylococci', 'biofilm', 'antimicrobial resistance', 'periprosthetic infection'], 'conditions': ['Prosthetic Joint Infection', 'Prosthetic Infection', 'Hip Prosthesis Infection', 'Knee Prosthesis Infection']}, 'referencesModule': {'references': [{'pmid': '27779811', 'type': 'BACKGROUND', 'citation': 'Zaborowska M, Tillander J, Branemark R, Hagberg L, Thomsen P, Trobos M. Biofilm formation and antimicrobial susceptibility of staphylococci and enterococci from osteomyelitis associated with percutaneous orthopaedic implants. J Biomed Mater Res B Appl Biomater. 2017 Nov;105(8):2630-2640. doi: 10.1002/jbm.b.33803. Epub 2016 Oct 25.'}, {'pmid': '36109038', 'type': 'DERIVED', 'citation': 'Tillander JAN, Rilby K, Svensson Malchau K, Skovbjerg S, Lindberg E, Rolfson O, Trobos M. Treatment of periprosthetic joint infections guided by minimum biofilm eradication concentration (MBEC) in addition to minimum inhibitory concentration (MIC): protocol for a prospective randomised clinical trial. BMJ Open. 2022 Sep 15;12(9):e058168. doi: 10.1136/bmjopen-2021-058168.'}]}, 'descriptionModule': {'briefSummary': "The overall purpose of this clinical treatment research project is to explore novel diagnostics that can guide the treatment of infections associated to orthopaedic implants, in order to improve patient outcomes and reduce the development of antibiotic resistance.\n\nThe project aims are:\n\n(i) To improve the current diagnostic approaches and treatments of periprosthetic joint infections (PJI) (ii) To investigate the pathogenesis of PJI through the characterization of the virulence carried by the causative pathogens\n\nThis multidisciplinary project addresses implant-associated infection and its contribution to increasing antibiotic resistance. Both lead to longer hospital stays, higher medical costs and increased morbidity and mortality. Antibiotic resistance is globally considered as one of the greatest and most urgent risk in medicine. Implant-associated infections are commonly caused by biofilms. Biofilms can be described as 'a community of bacterial cells connected by their secreted extracellular matrix'. Since antibiotics are designed to fight planktonic free-living bacteria, studying antibiotic resistance in biofilm communities poses a paradigm shift. Furthermore, bacteria in biofilms are up to 1000 times more resistant to antibiotics than planktonic bacteria. Mechanisms involved in a biofilm infection also play a crucial role in the development of antibiotic resistance. Hospital-acquired infections are the fourth leading cause of disease and 70% are associated with medical implants and caused by staphylococcal biofilms. In addition, the level of antimicrobial resistance in bacteria causing implant-associated infections has increased worldwide, leaving patients with fewer treatment options.\n\nIn this study the investigators will randomize patients with PJI to either standard MIC susceptibility or MIC and MBEC susceptibility guided treatment with oral antibiotic combinations; (i) Non cell wall active standard of care antibiotic combination (MIC-guided) for 6 weeks.\n\n(ii) Or; non cell wall active antibiotic combination according to a MBEC-based decision algorithm for 6 weeks.\n\nIn this pilot project, the primary endpoint is how often treatment changes with the MBEC susceptibility testing compared to only MIC-susceptibility testing.", 'detailedDescription': 'In the infectious process, biofilms may form early on biomaterials. There is ample evidence to the several-fold increase in antimicrobial concentrations required to eradicate even immature biofilms. In clinical practice the choice of antimicrobials is guided by susceptibility testing based on minimum inhibitory concentrations (MIC), which poorly reflect the increased antimicrobial resistance in biofilms. Minimum biofilm eradicating concentrations (MBEC) might better correspond to in vivo efficacy in the treatment of PJI, and other biofilm-centred infections. There is a need to develop methods, which are reproducible, low-cost, and time-efficient, for in vitro susceptibility testing of clinical biofilm bacteria.\n\nThis prospective randomized study aim to compare antibiotic treatment regimens for PJI guided by MIC or MBEC combined with MIC, and how it affects infection resolution, drug tolerability and relapse strain resistance patterns.\n\nThe investigors hypothesize that a standardised surgical debridement, antibiotics and implant retention (DAIR) for PJI followed by antibiotic guiding MBEC-diagnostics on deep tissue specimens will increase treatment efficacy and decrease the incidence of infection relapses compared to standard of care.\n\nFollowing standardised debridement and 14 days of parenteral antibiotics; cloxacillin for methicillin sensitive staphylococci or vancomycin for methicillin resistant staphylococci, patients will be randomized to receive oral antibiotic combinations with either cell wall active standard of care antibiotic combination (MIC-guided) for 6 weeks or non cell wall active antibiotic combination according to a MIC- and MBEC-guided decision algorithm for 6 weeks.\n\nPatients will be included at the Orthopaedic Infection Centre (OIC), Sahlgrenska University Hospital/Mölndal, which is a unit dedicated to optimizing management of orthopaedic infections. Patient consent acquisitions and randomisations (20 patients in each group) will be performed during post-operative hospitalisation. MIC determination and disk diffusion will be performed at the SWEDAC (Swedish Accreditation Body) certified clinical bacteriological laboratory. At the department of Biomaterials (University of Gothenburg), a previously developed clinical diagnostic tool will be employed for the MBEC determination. It consists of the combination of the Calgary Biofilm Device (MBECTM P\\&G Assay, Innovotech) and a custom-made susceptibility plate (Substrata department, Sahlgrenska Hospital) with 6 antimicrobial agents commonly used to treat orthopaedic infections.\n\nInclusion and exclusion criteria are described in section "Eligibility".\n\nThe primary and secondary endpoints are described in section "Outcome measures".\n\nTreatment criteria: for all administered antimicrobials staphylococcal strains must be susceptible in disc diffusion tests/MIC, regardless of MBEC-level. Antibiotic combinations will be selected from 5 already recommended non-cell wall active anti-staphylococcal antibiotics with high per-oral bio-availabilities and acceptable bone penetration used in the treatment of PJIs: rifampicin (RIF), fusidic acid (FUS), ciprofloxacin (CIP)/levofloxacin (LEV) and clindamycin (CLI).\n\nClinical breakpoints are expressed as MIC (EUCAST and CLSI) but are based on more than MIC distributions (epidemiological cut-off) namely:\n\n* Pharmacokinetic and pharmacodynamic analyses of the antibiotic.\n* Relation between MIC and probability of cure in clinical trials.\n\nIf likely effective according to EUCAST clinical breakpoints, antibiotics are further ranked in the MBEC treatment algorithm by bone penetration/susceptibility range and semi-arbitrarily by clinical efficacy in prosthetic joint infections.\n\nMBEC/MIC cut-off for replacing Rifampicin despite susceptibility according to MIC:\n\n* C-Max (oral dose of 750 mg) 10 mg/L x 0.4 (Bone/Serum) = 4 mg/L\n* RIF-MIC clinical breakpoint for staphylococci is 0.5 mg/L.\n* Clinical efficacy factor 1.\n* MBEC/MIC ≥ 8 times MIC.\n\nMBEC/MIC cut-off for replacing Levofloxacin despite susceptibility according to MIC:\n\n* C-Max (oral dose of 750 mg) 12 mg/L x 0.6 (Bone/Serum) = 7,2 mg/L\n* LEV-MIC breakpoint for staphylococci is 1 mg/L\n* Clinical efficacy factor 0,75.\n* MBEC/MIC ≥ 5 x MIC.\n\nMBEC/MIC cut-off for not choosing Fusidic acid as companion drug:\n\n* C-Max (500 mg) 30 mg/L x 0,2 (Bone/Serum) = 6 mg/L\n* FUS-MIC breakpoint for staphylococci is 1 mg/L.\n* Clinical efficacy factor 0,5.\n* MBEC 3 times the MIC or more if better companion drug.\n\nMBEC/MIC cut-off for not choosing Clindamycin as companion drug:\n\n* C-Max (600 mg) 12 mg/L x 0.3 (Bone/Serum) = 3,6 mg/L\n* CLI-MIC breakpoint for staphylococci is 0.5 mg/L\n* Clinical efficacy factor 0,5.\n* MBEC/MIC 4 x MIC or more if better companion drug.\n\nMBEC/MIC cut-off for not choosing Linezolid (LIN) as sole drug:\n\n* C-Max 21 mg/L x 0.4 (Bone/Serum) = 8,4 mg/L\n* LIN-MIC breakpoint for staphylococci is 4 mg/L\n* Clinical efficacy factor 0,5.\n* MBEC 2 times the MIC or more.\n\nMBEC cut-off for not choosing Sulfamethoxazole (SMX)/Trimethoprim (TMP) as sole drug:\n\n* C-Max (3200/640 mg SMX/TMP) is 145 and 7.5 mg/L resp. x 0.25 (Bone/Serum) = 36 and 1,9 mg/L resp.\n* SMX/TMP-MIC breakpoint for staphylococci is 2 mg/L. (By EUCAST expressed as the Trimethoprim konc.)\n* Clinical efficacy factor 0,5.\n* MBEC \\> MIC\n* \\*Interpret as better than according to justification above.\n\nAll follow-up up to one year will be done according to clinical routines.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'minimumAge': '18 Years', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion Criteria:\n\n* first PJI in hip or knee according to Musculoskeletal Infection Society (MSIS) definitions\n* first DAIR\n* mono-microbial staphylococcal infection\n* 14 days of intravenous treatment with either cloxacillin or vancomycin\n* standardized administration of local antibiotics\n\nExclusion Criteria:\n\n* allergy/previous toxic event/unacceptable drug interaction to most effective antibiotic combination according to either MIC or MBEC\n* severe drug interactions to MBEC-guided compound'}, 'identificationModule': {'nctId': 'NCT04488458', 'briefTitle': 'Susceptibility Testing of Biofilm to Guide Treatment of Periprosthetic Joint Infections', 'organization': {'class': 'OTHER_GOV', 'fullName': 'Vastra Gotaland Region'}, 'officialTitle': 'Treatment of Periprosthetic Joint Infections Guided by Minimum Biofilm Eradication Concentration (MBEC) in Addition to Minimum Inhibitory Concentration (MIC); a Prospective Randomized Clinical Trial', 'orgStudyIdInfo': {'id': '2020-01471'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'MBEC and MIC susceptibility testing', 'description': 'For all administered antimicrobials staphylococcal strains must be susceptible in disc diffusion tests/MIC, regardless of MBEC-level. Antibiotic combinations will be selected from 5 already recommended non-cell wall active anti-staphylococcal antibiotics with high per-oral bio-availabilities and acceptable bone penetration used in the treatment of PJIs: rifampicin, fusidic acid, ciprofloxacin/levofloxacin and clindamycin.\n\nMBEC cut-off for replacement with 2nd or 3rd line antibiotic: RIF MBEC/MIC \\> 8; LEV MBEC/MIC \\> 5; FUS MBEC/MIC \\> 3; CLI MBEC/MIC \\> 4; LIN MBEC/MIC \\> 2; T/S MBEC \\> MIC\n\nSecond line of treatment:\n\nRIF and Fusidic acid 500 mg TID (ter in die) RIF and Clindamycin 450 - 600 mg TID LEV and Fusidic acid 500 mg TID LEV and Clindamycin 450 mg TID\n\nThird line of treatment:\n\nLinezolid 600 mg BID (bis in die) Sulfamethoxazole/Trimethoprim 800/160 mg TID Clindamycin 450 mg TID and Fusidic acid 500 mg TID', 'interventionNames': ['Diagnostic Test: MIC or MBEC+MIC based treatment algorithm']}, {'type': 'ACTIVE_COMPARATOR', 'label': 'MIC susceptibility testing', 'description': 'If the causative bacterium is susceptible according to MIC diagnostics, the patient will follow the first line of treatment: Rifampicin 750-900 mg/day + Levofloxacin 750 mg BID', 'interventionNames': ['Diagnostic Test: MIC or MBEC+MIC based treatment algorithm']}], 'interventions': [{'name': 'MIC or MBEC+MIC based treatment algorithm', 'type': 'DIAGNOSTIC_TEST', 'description': 'i) Non cell wall active standard of care antibiotic combination (MIC-guided) for 6 weeks.\n\nii) Non cell wall active antibiotic combination according to a MBEC-based decision algorithm for 6 weeks.', 'armGroupLabels': ['MBEC and MIC susceptibility testing', 'MIC susceptibility testing']}]}, 'contactsLocationsModule': {'locations': [{'city': 'Mölndal', 'status': 'RECRUITING', 'country': 'Sweden', 'contacts': [{'name': 'Ola Rolfson, PhD', 'role': 'CONTACT', 'email': 'ola.rolfson@vgregion.se'}], 'facility': 'Ortopedi, Sahlgrenska University Hospital', 'geoPoint': {'lat': 57.6554, 'lon': 12.01378}}], 'centralContacts': [{'name': 'Ola Rolfson, Professor', 'role': 'CONTACT', 'email': 'ola.rolfson@vgregion.se', 'phone': '+46 313430852'}]}, 'ipdSharingStatementModule': {'ipdSharing': 'NO', 'description': "The main results will be presented at an aggregated level. In some cases, individual data may be presented (e.g. characteristics of a bacterial strain in relation to clinical outcome), but this information will be unidentified so that it cannot be deduced to the individual.\n\nAll compiled personal data will be stored on a password-protected hospital server that only the research group has access to. No personal data will be reported in publications.\n\nThe results of the study will be documented according to the study protocol and placed in a journal. Participants will be coded in a document together with the social security numbers.\n\nInformation about the participants, their health and the code key will be collected at the Orthopaedic Clinic where it will be treated confidentially and securely for 10 years. The handling of the participants' information is regulated by the Personal Data Act (SFS 1998: 204)."}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Vastra Gotaland Region', 'class': 'OTHER_GOV'}, 'collaborators': [{'name': 'Göteborg University', 'class': 'OTHER'}], 'responsibleParty': {'type': 'SPONSOR'}}}}